08.01.13
Charles River Laboratories
2Q Revenues: $292.9 million (+3%)
2Q Earnings: $27.7 million (-9%)
YTD Revenues: $584.2 million (+2%)
YTD Earnings: $53.5 million (-6%)
Comments: Research Models and Services (RMS) revenues were $179.0 million in the quarter, up 3% driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) sales were $114.0 million, up 3% driven by increased sales to both large biopharmaceutical and mid-tier clients, primarily as a result of market share gains. Lower operating income was the primary driver of the decline in earnings.
2Q Revenues: $292.9 million (+3%)
2Q Earnings: $27.7 million (-9%)
YTD Revenues: $584.2 million (+2%)
YTD Earnings: $53.5 million (-6%)
Comments: Research Models and Services (RMS) revenues were $179.0 million in the quarter, up 3% driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) sales were $114.0 million, up 3% driven by increased sales to both large biopharmaceutical and mid-tier clients, primarily as a result of market share gains. Lower operating income was the primary driver of the decline in earnings.